A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain
CompletedPhase 3NCT00631319
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
To evaluate the efficacy of OROS Hydromorphone in reducing moderate to severe chronic pain in patients with Osteoarthritis (OA) Pain
Study details
- Official title
- A Phase III, Flexible Dose Titration Followed by a Randomized Double-Blind Study of Controlled Release OROS Hydromorphone HCL Compared to Placebo in Patients With OA Pain
- Conditions
- Interventions
- Drug: OROS hydromorphone
- Drug: Placebo
- Sponsor
- Mallinckrodt
- Start date
- 2008-02
- Primary completion
- 2009-04
- Sex
- All
- Age range
- from 30 Years to 80 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria * Primary clinic diagnosis of osteoarthritis pain of the hip or of the knee for at least 6 months * Patients required daily opioid medication to treat their chronic osteoarthritis pain Exclusion Criteria * Joint replacement of the hip or of the knee that is the primary source of osteoarthritis Pain * History drug or alcohol abuse * Fibromyalgia * Patients who have major depression or anxiety * Women who are pregnant or breast feeding
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00631319